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Abstract
Background—Although case-control approaches are beginning to disentangle schizophrenia’s 
complex polygenic burden, other methods will likely be necessary to fully identify and 
characterize risk genes. Endophenotypes, traits genetically correlated with an illness, can help 
characterize the impact of risk genes by providing genetically relevant traits that are more 
tractable than the behavioral symptoms that classify mental illness. Here we present an analytic 
approach for discovering and empirically validating endophenotypes in extended pedigrees with 
very few affected individuals. Our approach indexes each family member’s risk as a function of 
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shared genetic kinship with an affected individual, often referred to as the coefficient of 
relatedness. To demonstrate the utility of this approach, we search for neurocognitive and 
neuroanatomic endophenotypes for schizophrenia in large unselected multigenerational pedigrees.
Methods—A fixed effect test within the variance component framework was performed on 
neurocognitive and cortical surface area traits in 1,606 Mexican-American individuals from large, 
randomly ascertained extended pedigrees who participate in the “Genetics of Brain Structure and 
Function” study. As affecteds are excluded from analyses, results are not influenced by disease 
state or medication usage.
Results—Despite having sampled just 6 individuals with schizophrenia, our sample provided 
233 individuals at various levels of genetic risk for the disorder. We identified three 
neurocognitive measures (digit-symbol substitution, facial memory, and emotion recognition) and 
six medial temporal and prefrontal cortical surfaces associated with liability for schizophrenia.
Conclusions—With our novel analytic approach one can discover and rank endophenotypes for 
schizophrenia, or any heritable disease, in randomly ascertained pedigrees.
Keywords
endophenotype; schizophrenia; family study; coefficient of relatedness; cognition; cortical surface 
area
Introduction
Susceptibility loci for schizophrenia were recently localized using population-based 
genome-wide association (GWA) methods that focus on common variants (1–8). Although 
these loci represent an important advance towards unraveling the genetic architecture of the 
illness, the number of causal gene identifications is limited and identified loci explain only a 
small proportion of the heritable risk (9). A recent whole exome sequence study examined 
2,536 schizophrenia cases and 2,543 controls, providing the strongest evidence to date for 
specific genetic variants that increase risk for psychosis (10). Purcell and colleagues (2014) 
identified numerous rare (<1 in 10,000) mutations across many genes, that when considered 
in aggregate are strongly associated with schizophrenia risk. However, no individual variant 
or gene-based test achieved statistical significance, suggesting a complex polygenic burden 
increases risk for schizophrenia through multiple targets within one or more metabolic 
pathways. Although it is possible that with additional samples individual rare variants 
identified through exome or whole genome sequencing may become significant, these 
findings clearly demonstrate the polygenic nature of schizophrenia risk (11). Going forward, 
it is critical to systematically examine the impact of risk variants on empirically derived 
gene sets or bioinformatically validated gene networks to elucidate how genetic processes 
predispose the complex behavioral symptoms that define schizophrenia. Yet, even for 
Mendelian disorders with known mutations the biological mechanisms that span the space 
between genotype and clinical phenotype are often unclear. It is likely that polygenic 
diseases, like psychiatric illnesses, will have even more complex genotype-phenotype 
relationships. For this reason, quantitative traits, rather than bifurcated diagnoses, are better 
suited for modeling complex gene effects (12), as they provide a relative ranking of 
individuals along an assumed continuum. One dilemma for psychiatric genetics, then, is 
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developing techniques for understanding the impact of sets of risk genes on the 
neurobiological antecedents of mental illness. Based primarily on work in other areas of 
medicine (e.g. (13)), it is clear that the use of well designed and validated allied phenotypes, 
intermediate phenotypes or endophenotypes should facilitate this process by characterizing 
the effects of disruptions in gene networks on traits closely aligned to the illness (14).
Endophenotypes that are sensitive to the genetic liability for an illness that can characterize 
the pathways through which genetic variation gives rise to clinical phenomenon (15). An 
endophenotype is a heritable trait that is genetically correlated with disease liability, 
providing greater power to localize and characterize the mechanisms of disease-related 
genes than diagnostic status alone (15–18). Typically, endophenotypes are identified 
through twin or family studies where probands are selected for a specific illness (19). Many 
studies have more complex recruitment strategies (e.g. (20–23)), requiring multiple affected 
individuals in order to maximize the potential that the proband has a genetic, rather than 
sporadic, form of the illness. However, such ascertainment strategies can complicate both 
genetic and endophenotypic inference (24). An alternate approach is to study families that 
were not selected for a specific phenotype. For common illnesses like major depression, 
with lifetime prevalence rates approaching 15% (25), random epidemiological sampling 
methods should provide adequate samples of affected individuals without obvious 
ascertainment bias. Utilizing a similar approach in large extended pedigrees, we recently 
discovered a number of behavioral, neuroanatomical and transcriptional endophenotypes for 
major depression (18). Combining one of these endophenotypes, the RNF123 lymphocyte-
based transcript, in a bivariate quantitative trait locus (QTL) localization analysis provided a 
novel locus for major depression (18), an illness whose genetic structure is still an enigma 
(26).
It is possible that even with rarer illnesses like schizophrenia (e.g. ~1% prevalence) 
endophenotypes can be identified in unselected samples, assuming pedigree sizes are large 
enough to model pleiotropy between endophenotype and illness. Using large unselected 
families could benefit our search for empirically validated schizophrenia endophenotypes 
and establish a foothold for disentangling the illnesses complex polygenic burden. To do so 
requires analytic approaches optimized for assessing endophenotypic variation of a 
relatively small number of affected individuals in the context of their larger family. One 
such analytic approach, developed here, indexes each person’s illness risk as a function of 
genetic kinship with an affected individual. That is, a first degree relative of an affected 
individual is expected to share approximately 50% of their genetic variation, while a second 
degree relative is anticipated to have 25% of shared genetic variation with a similar halving 
of genetic sharing for each subsequent degree of relatedness. We show that such an index, 
often referred to as the coefficient of relationship, can be used to perform a fixed effect 
single-degree of freedom test within a variance component analysis, providing genetic 
correlation information between a trait of interest and the illness and thus showing that the 
measure is a candidate endophenotype for the disease.
In the present manuscript, we search for neurocognitive and neuroanatomic endophenotypes 
for schizophrenia in large multigenerational pedigrees using a novel approach to the 
estimation of the endophenotypic ranking value (ERV) which is closely related to the genetic 
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correlation between endophenotype and disease. Specifically, we test the hypothesis that 
individual brain-related traits are sensitive to genetic liability for schizophrenia, even in 
extended pedigrees with few affected individuals.
Materials and Methods
Participants
1,606 Mexican-American individuals from large extended pedigrees (75 pedigrees, average 
family size 21.41 [2–126] people) who participate in the “Genetics of Brain Structure and 
Function” study were included in the analysis. Individuals in this cohort have actively 
participated in research for over 20 years and were selected from a single census track in 
south San Antonio without regard to psychiatric diagnosis, with the constraints that they 
were of Mexican-American ancestry and part of a large family (see (27, 28) for recruitment 
details). No other inclusion or exclusion criteria were imposed in the initial study. However, 
individuals were excluded from the neurocognitive evaluation for history of neurological 
illnesses, stroke or other major neurological event. Individuals were excluded from the 
neuroimaging evaluation for these criteria and for MRI contraindications. Reported pedigree 
relationships were empirically verified, based on autosomal markers, and intra-familial 
relationships were edited if necessary. All participants provided written informed consent on 
forms approved by the IRBs at the University of Texas Health Science Center San Antonio 
(UTHSCSA)/Texas Biomedical Research Institute and at Yale University.
Diagnostic Assessment
All participants received face-to-face medical history and psychiatric interviews. The Mini-
International Neuropsychiatric Interview (29) (MINI-Plus), a semi-structured interview to 
facilitate diagnoses of DSM-IV and ICD-10 psychiatric illnesses, was augmented to include 
items on lifetime diagnostic history. Masters and doctorate level research staff, with 
established reliability (κ≥0.85) for psychotic and affective disorders, conducted all 
interviews. All subjects with possible psychopathology were discussed in case conferences 
that included licensed psychologists or psychiatrists, and lifetime consensus diagnoses were 
determined.
Neurocognitive Assessment
Each participant received a 90-min neuropsychological evaluation (21, 30, 31). 
Neuropsychological tests include standard clinical measures and well-validated 
computerized tasks (32–34). Twenty neurocognitive variables were derived from 16 
neuropsychological tests, including measures of attention/concentration, executive 
processing, working memory, declarative memory, language processing, intelligence and 
emotional processing. Eight percent of sample was tested in Spanish and test instructions 
were translated into Spanish and back translated into English.
Neuroimaging Assessment
Images were acquired on a research-dedicated, Siemens 3T Trio/TIM scanner with a 32-
element high-resolution phase array head coil housed in the Research Imaging Institute, 
UTHSCSA. Neuroanatomic images included seven high-resolution T1-weighted 3D Turbo-
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FLASH sequences with an adiabatic inversion contrast pulse and the following parameters: 
TE/TR/TI = 3.04/2100/785 ms, flip angle=13°, 800µm isotropic resolution, 200mm FOV, 5-
min duration (35-min total). A retrospective motion correction protocol was implemented to 
improve signal to noise (35). Image processing was based on cortical surface representations 
using FreeSurfer (http://surfer.nmr.mgh.harvard.edu/). The analysis followed previously 
described procedures (36, 37) as implemented in our group (38). Images underwent 
inhomogeneity corrections, intensity normalization, linear alignment to a common atlas 
space, and skull removal. Next, white matter voxels were identified based on location and 
relative intensity. The two hemispheres were separated and a tessellated mesh was built 
around the mass of white matter voxels. This mesh was smoothed with an algorithm that 
takes into account the local intensity in the original images and topological defects are 
corrected. The resulting smoothed mesh represented the white matter surface. The gray 
matter (pial) surface was generated by expanding the white surface to the gray matter/CSF 
boundary while constraining the smoothness of the surface. Gray and white matter surfaces 
were visually inspected and manually edited if necessary. Next, the pial surface was inflated 
into a sphere, registered to an atlas utilizing cortical folding patterns and segmented into 
regions of interest based on gyral and sulcal structure, surface curvature and sulcal depth 
(39, 40). More specifically, a Bayesian approach was applied to establish the probability that 
a given vertex belonged to a given label based on a probability atlas. Surfaces were parceled 
into 33 regions of interest per hemisphere defined by the Desikan-Killiany atlas (2006). 
Eight subcortical regions were parceled using similar procedures and volumetric measures 
were calculated.
Quantitative Genetic Analysis
Quantitative genetic analysis was used to partition trait covariance among related individuals 
into genetic and environmental components. For a trait, the phenotypic covariance matrix 
(Ω) in a pedigree of n members was modeled as  where R is the n×n kinship 
matrix for the pedigree,  is the variance in the trait due to additive genetic effects, I is an 
n×n identity matrix, and  is the variance due to random environmental effects. The 
additive genetic heritability (h2) of a trait is defined as: . Prior to analysis, 
candidate endophenotypes were normalized using an inverse Gaussian transformation. Age, 
age2, sex, and their interactions (age×sex, age2×sex) were included as covariates to model 
mean effects. In addition, intracranial volume was included as a covariate for FreeSurfer 
analyses. Regression terms were estimated for each covariate, and the likelihood of a model 
in which the covariate effect was estimated was compared to the likelihood of a model in 
which the covariate effects were constrained to zero. To control for multiple comparisons 
within each endophenotype class, the false discovery rate (FDR) was set to q=0.05.
Estimating the Endophenotypic Ranking Value in Randomly Ascertained Pedigrees
An endophenotype must be heritable and genetically correlated with disease liability (18). 
Glahn and colleagues (2012) proposed the endophenotype ranking value (ERV) to formally 
test for endophenotypic status and to rank potential endophenotypes. The ERV provides an 
unbiased and empirically derived method for identifying and choosing appropriate 
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endophenotypes in a manner that balances the strength of the genetic signal for the 
endophenotype and the strength of its relation to the disorder of interest. It is defined as the 
product of the square-root of the heritability of the disease ( ) on the continuous liability 
scale under the assumption of a normal threshold model, the square-root of the heritability of 
the endophenotype ( ), and the genetic correlation (ρG) between liability and 
endophenotype. The ERV is expressed in the following formula:
The ERV is a standardized genetic covariance with values varying between 0 and 1, where 
higher values indicate that the endophenotype and the illness are more strongly influenced 
by shared genetic factors. The ERV was previously used in situations where all component 
parameters ( ) were directly estimated from a given data set. Direct estimation of 
these parameters requires a pedigree-based study design with sufficient disease cases, either 
with relatively common illnesses (prevalence of ≥10%) or in heavily ascertained pedigrees. 
In this context, all three parameters (and the ERV) are simultaneously estimated using a 
standard bivariate quantitative genetic variance component model (18). However, when a 
disease is less common, such as schizophrenia, we show that it is possible to estimate the 
ERV from even randomly selected pedigree designs if there is a sufficient number of 
relatives of disease cases. Rewriting the underlying covariance model as a fixed effects 
model provides information on the ERV in terms of differences in the mean endophenotypic 
values of unaffected relatives of affected individuals versus those of unaffected individuals 
who have no known relatives with the disease.
Consider a disease that is determined by a normal threshold process on a continuous latent 
liability (l) such that the population prevalence can be written
where fN () is a standard normal probability density function with mean 0 and unit variance 
and t is the threshold above which an individual’s liability is scored as a disease. The 
heritability of the disease on the latent liability scale is closely related to that on the 
observed binary scale when affected individuals are scored as a 1 and unaffected individuals 
as a 0:
using the transformation first developed by Dempster and Lerner (41).
To rewrite the variance/covariance terms of the ERV in terms of observable mean effects, we 
consider the expectations for differences in means of a putative endophenotype between 
unaffected relatives of an individual with the disease versus unaffected individuals without 
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an affected relative. Let μR be the mean of the endophenotype (y) in a set of individuals who 
are related to an affected individual with coefficient of relationship rD and μU be the mean in 
individuals who are unrelated to any affected individual. After some algebra relating mean 
effects to covariance components, the ERV can be rewritten on the binary scale in terms of 
the standardized difference in means between these two groups as:
where σ is the standard deviation of the endophenotype. Transforming to the underlying 
normal liability scale yields
This formula utilizing subgroup means to detect genetic correlation can be used for any pair-
wise relationship. However, we are interested in utilizing all joint information to make 
inferences about the identity and suitability of prospective endophenotypes. We can further 
generalize this model to any set of arbitrary relatives by utilizing a linear model for the mean 
in the set of relatives of affected individuals in which μR =μU + β max(rD) where the 
coefficient of relationship between every individual and his closest affected relative is 
employed as a covariate with regression coefficient, β, for the endophenotype. Additionally, 
covariates such as those including sex and age (as described above) can also be included as 
needed. Using this extended model, the ERV can be written as
Thus, a test of the significance of β (using a standard likelihood ratio test statistic) represents 
a formal test of the ERV which requires that there be both a heritable basis for the disease 
and a genetic correlation of the endophenotype with the disease. Given that we perform this 
fixed effect estimation and testing in pedigree data, we can simultaneously (and explicitly) 
obtain an estimate of the heritability ( ) of the endophenotype itself. We implemented the 
ERV estimation approach as a mixed linear model in the computer package, SOLAR (42).
Results
Family Profiles
Based upon our consensus diagnostic process, 6 of the 1606 individuals met criteria for 
lifetime schizophrenia. Individuals with schizophrenia were 46.87 years of age (13.45 SD, 
34–67), had 10.50 years of education (2.88 SD, 7–14) and were male. Each affected 
individuals was from an unique pedigree and together they were related to 233 non-
schizophrenic relatives, including 14 unaffected 1st degree relatives, 17 unaffected 2nd 
degree relatives, and so on, as shown in Table 1.
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1,560 individuals had valid neurocognitive data, including 220 non-schizophrenic relatives. 
As can be seen in Table 2, all of the neurocognitive tests were heritable and strongly 
influenced by age. Three neurocognitive tests were sensitive to genetic liability for 
schizophrenia: digit symbol substitution (β̂ = −1.59; ERV = 0.591), delayed facial memory (β̂ 
= −1.48; ERV = 0.550) and emotion recognition (β̂ = −1.39; ERV = 0.516). Each of these 
tests has previously been associated with schizophrenia risk (30, 43).
Gray-Matter Endophenotypes
997 individuals had T1-weighted images processed in FreeSurfer at the time of the analysis, 
including 137 non-schizophrenic relatives. Bilateral cortical surface area estimates were 
uniformly heritable (see Table 3 and Figure 1). After controlling for multiple comparisons, 
six regions were significantly and negatively associated with schizophrenia risk: the 
fusiform gyrus (β̂ = −1.62; ERV = 0.601), the entorhinal cortex (β̂ = −1.73; ERV =0.643), the 
parahippocampal gyrus (β̂ = −1.66; ERV = 0.615), the precuneus (β̂ = −1.56; ERV = 0.581), 
inferior temporal gyrus (β̂ = −1.49; ERV = 0.553) and superior frontal gyrus (β̂ = −1.49; ERV 
= 0.554). These predominately frontal and temporal regions have been previously implicated 
in the pathophysiology of schizophrenia (44) and there is limited evidence that surface area 
in these regions is associated with risk for the illness (45).
In contrast to surface area measurements, no subcortical volume was statistically associated 
with risk for schizophrenia after correcting for multiple comparisons. However, amygdala 
volume trended towards statistical significance (β̂ = −1.26; ERV = 0.470).
Discussion
We used large extended pedigrees unselected for mental illness to identify and rank 
neurocognitive and neuroimaging endophenotypes for schizophrenia. Although our sample 
contained few cases with schizophrenia, our results strongly suggest that reliable genetic 
correlation information is embedded and available in these extended pedigrees. The 
identified neurocognitive measures are strikingly consistent with prior endophenotype 
searches in schizophrenia (22, 23, 46, 47) and bipolar disorder (21), providing validity for 
our experimental approach and analytic procedure. The cortical surface area findings 
generally replicate and extend the prior literature (44, 45, 48). This method of ERV testing 
and estimation has several benefits over the standard variance/covariance approach. First, 
the method provides a test of means, which are consistently more powerful than tests of 
variances/covariances (49). Second, the endophenotypic data of affected individuals is not 
included in ERV estimation. Hence, the ERV is not influenced by disease state or medication 
usage. Finally, the test can be used even when there are few affected individuals in the 
sample if there are sufficient numbers of unaffected relatives. The current analytic and 
experimental tactic provides a novel approach for discovering and ranking endophenotypes 
for schizophrenia or any heritable disease.
It is important to note that the use of large extended pedigrees is critical for this analytic 
strategy. Despite having sampled just 6 individuals with schizophrenia (who were not 
Glahn et al. Page 8













included in the focal analyses), our sample provided 233 individuals at various levels of 
genetic risk for the disorder. While our method could work with any family-based design 
(e.g. twin pairs or trios), an advantage of large extended pedigrees is that many unaffected 
relatives should be available for even a small number of cases, providing the statistical 
power needed to adequately test hypotheses about putative pleiotropy between 
endophenotype and illness. To further demonstrate the utility of extended pedigrees, we 
conducted additional analyses while excluding affected individuals as well as their 
unaffected first-degree relatives (n=14), dramatically reducing common environmental 
influences between individuals with schizophrenia and their more distantly related family 
members. Results of these analyses were generally similar to those reported above (see 
Supplement), speaking to the robustness of our approach and suggesting that common 
environmental influences did not drive our results. A benefit of phenotypically randomly 
selected large extended pedigrees is that many different endophenotypes can be analyzed in 
a single study, yielding substantial efficiency as phenotypes are added. As the genetic 
architectures of other mental illnesses are likely to be as complex as that of schizophrenia, 
involving multiple common and rare mutations within a common gene pathway (50, 51), we 
anticipate that very well characterized unselected pedigrees will be critical for testing 
biological hypotheses about the impact of particular gene networks on illness risk.
Neurocognitive measures are quintessential endophenotypes for schizophrenia (52). 
Neurocognitive traits are highly heritable (53), patient deficits are generally severe or very 
severe (54), and their expression is often concordant in unaffected relatives (22, 47, 55–57). 
We identified three neurocognitive measures related to liability for schizophrenia: the 
number correct on the digit-symbol substitution task (23, 32), a processing speed measure; 
the number of items recognized on the Penn Facial Memory Test (58), a test of declarative 
memory; and the number of correctly identified emotions portrayed on 40 ctors (33). Each 
of these tests was previously associated with schizophrenia risk. Indeed, the identical digit 
symbol substitution was also found to be the measure most strongly associated with 
schizophrenia in an independent sample of Latino pedigrees selected for a sibling pair 
concordant for the illness (30). Re-analyzing these data, the estimated ERV statistic for digit 
symbol performance was 0.493 in this sample, similar to the 0.591 observed here. 
Processing speed deficits, particularly those indexed by the digit-symbol substitution task, 
appear to be a central feature of the cognitive deficit in schizophrenia (59, 60). Similarly, the 
identical facial memory was associated with schizophrenia risk in 35 multiplex 
multigenerational families of European ancestry (55). Facial memory impairment, and 
declarative memory more generally, is consistently liked to risk for the illness (22, 47, 55). 
While fewer investigators have examined the link between emotion recognition and 
schizophrenia risk, work by the Consortium on the Genetics of Schizophrenia (COGS) 
recently demonstrated a link between the same task applied here and illness liability, 
potentially mediated through a locus on 1p36 (61). Other neurocognitive measures were 
similarly sensitive to genetic liability for schizophrenia with high ERV values but did not 
exceed our correction for multiple comparisons: verbal fluency (ERV = 0.498), letter-
number span (ERV = 0.545) a working memory measure, trails B (ERV = 0.538) an 
executive functioning task, and the WASI IQ and vocabulary indies (ERV = 0.509 and 
0.589, respectively).
Glahn et al. Page 9













Although meta-analyses report evidence for volumetric reductions in thalamus, 
hippocampus, anterior cingulate cortex, corpus callosum area, and increased ventricular size 
in schizophrenia (62, 63), findings in unaffected relatives has been mixed (48, 64, 65). It is 
possible that the methods for measuring neuroanatomical variation are critical for this 
variability in the literature (38). Here, we focused on measures of cortical surface area as 
there is increasing evidence for areal disruptions in schizophrenia (66), and in their 
unaffected relatives (45, 67). We identified six regions with reduced surface area in those at 
risk for schizophrenia within the medial and lateral temporal lobes, the prefrontal cortex and 
the precuneus cortex. Portions of the cingulate gyrus previously noted as schizophrenia 
endophenotypes were likewise associated with illness risk and as having high ERV values 
(e.g. caudal anterior cingulate gyrus ERV = 0.516). However, these measures did not survive 
correction for multiple comparisons. It is tempting to suggest that the medial temporal 
cortex regions associated with schizophrenia risk, which includes the entorhinal and 
parahippocampal gyri, that are spatially proximal and involved in declarative memory, and 
the fusiform gyrus, that is involved in facial processing (68), could also be associated with 
the facial memory endophenotype identified in this sample, providing a parsimonious link 
between neurocognitive and neuroanatomic endophenotypes.
Using a newly derived variant of the endophenotype ranking value (ERV) statistic based 
upon the coefficient of relationship, we demonstrate that large unselected pedigrees can 
provide evidence that a measure is a candidate endophenotypes for schizophrenia and rank 
those endophenotypes according to their genetic covariance with the illness.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ERV Statistics Associating Variation in Cortical Surface Area with Schizophrenia Risk
Applying a novel analytic approach for discovering and empirically validating 
endophenotypes in extended pedigrees with very few affected individuals, we demonstrate 
that common genetic factors influence liability for schizophrenia and the FreeSurfer derived 
cortical surface area in six medial temporal and prefrontal regions (see Table 3 for details).
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